Onco Wiki - Drogas

Temozolomide

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDDRUG-TEMOZOLOMIDE
TipoFármaco
Aliaces
El TemodalTemodarТемозоломід
Situaciónreviewed 2026-04-26 | pending_clinical_signoff
EnfermedadesDIS-GBM
FuentesSRC-EANO-GBM-2024 SRC-NCCN-CNS-2025

Datos sobre drogas

ClaseAgente alquilante oral (imidazotetrazina)
MecanismoMethylates DNA at O6/N7 of guanine. Crosses blood-brain barrier efficiently — backbone of Stupp protocol for newly-diagnosed glioblastoma (concurrent + adjuvant). MGMT promoter methylation predicts response (methylated → ~3× longer OS benefit vs unmethylated).
Dosificación típicaGBM Stupp concurrent: 75 mg/m² PO daily during RT (6 weeks). GBM Stupp adjuvant: 150-200 mg/m² PO days 1-5 of every 28-d cycle × 6 cycles (start at 150, escalate to 200 if tolerated).
Ucrania registradaCierto
NSZU reembolsadoCierto
Ucrania verificada por última vez2026-04-27

Advertencias

Notas

PJP prophylaxis (TMP-SMX 1 SS Mon/Wed/Fri or atovaquone 1500 mg daily, alternative dapsone 100 mg daily after G6PD screen) during concurrent RT + TMZ phase and adjuvant TMZ phase — universal lymphopenia (typically CD4 <200) creates opportunistic-infection risk window persisting weeks after the last cycle. MGMT promoter methylation testing is critical for treatment decision (Stupp NEJM 2005; Hegi NEJM 2005): methylated → ~3× greater OS benefit vs unmethylated. NOA-08 + Nordic trials: in elderly (>65) unmethylated → consider hypofractionated RT alone; methylated → TMZ-only or short-course RT + TMZ. CCNU + TMZ doublet (CeTeG/NOA-09) showed OS benefit in MGMT-methylated newly-dx GBM. Premedicate with 5-HT3 (ondansetron 8 mg) 1 hour before each dose; Mon-Fri schedules ease antiemetic burden. CBC weekly during concurrent RT, q2 weeks during adjuvant. UA: registered; НСЗУ-reimbursed for GBM (Stupp) + anaplastic glioma.

Utilizado por

Esquema terapéutico